Biopharmaceutical company NeuroVia Inc declared on Wednesday that it has commenced a Phase 1/2 clinical study of its lead drug candidate, NV1205, for the treatment of patients with childhood cerebral adrenoleukodystrophy (CCALD).
According to the company, the Phase 1/2 study (ClinicalTrials.gov Identifier: NCT03196765) is designed to assess the safety, tolerability and pharmacokinetics of increasing doses of NV1205 in patients diagnosed with CCALD. It will be conducted in eight countries: Argentina, Australia, Chile, Colombia, France, the Russian Federation, Ukraine and the UK.
The most advanced product candidate, Lenti-D, is in a recently-initiated phase 2/3 study for the treatment of childhood cerebral adrenoleukodystrophy (CCALD
), a rare, hereditary neurological disorder affecting young boys.